packageDaclizumab

daclizumab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Daclizumab, a monoclonal antibody immunosuppressant, was used to treat multiple sclerosis and to prevent graft rejection in kidney transplantation. It has been withdrawn from the market, including its authorised products in the European Union, and is no longer in use.

Summary written by glm-5.3-flash from Wikidata Q412920 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:daclizumab
ATC codes:L04AA08, L04AC01
DrugBank:DB00111
Wikidata:Q412920
molar mass:142612 g/mol (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown